Login to Your Account

New Antibody Platform Leads Genmab Stock To New High

By Nuala Moran

Wednesday, October 25, 2006
LONDON - Shares in Genmab A/S reached a record high of DKK267 (US$45) after the Danish antibody company unveiled a stripped-down antibody construct, Unibody, and outlined progress in the development of the clinical portfolio at an R&D update meeting held here last week. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription